ClinicalTrials.gg

Program

aprocitentan

Also written as “Aprocitentan”, “Aprocitentan 25 mg” and “Aprocitentan tablets(SYH9108)”.

Its studies are mostly in Hypertension · Liver Diseases · Essential Hypertension · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since May 17, 201814 company-led studies, 1 open or runningNext primary completion: Dec 28, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticals130 open or runningphase 3since May 17, 2018Nov 9, 2015none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since May 29, 2026May 29, 2026Dec 28, 2029phase 3 · NCT07635914

Also a collaborator on its studies: Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2015First study: phase 2 study in Essential HypertensionNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT02603809 · 1,659 enrolled · United States, Canada, Israel and more
  2. Feb 24, 2016Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT02708004 · 24 enrolled · Switzerland
  3. Jul 20, 2016Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT02841761 · 20 enrolled · United States
  4. Mar 29, 2017Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03100591 · 6 enrolled · Netherlands
  5. May 23, 2017Phase 1 study in Renal InsufficiencyIdorsia Pharmaceuticals · NCT03165071 · 16 enrolled · Czechia
  6. Aug 8, 2017Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03245229 · 20 enrolled · Czechia
  7. May 17, 2018Phase 3 study in Resistant HypertensionIdorsia Pharmaceuticals · NCT03541174 · 730 enrolled · United States, Australia, Belgium and more
  8. Jul 2, 2018Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03586570 · 20 enrolled · United States
  9. Nov 11, 2019Phase 3 study in HypertensionIdorsia Pharmaceuticals · NCT04162366
  10. Jan 31, 2020Phase 1 study in Liver DiseasesIdorsia Pharmaceuticals · NCT04252495 · 17 enrolled · Germany, Poland
  11. Feb 20, 2020Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT04281342 · 48 enrolled · Germany
  12. Jan 5, 2022Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT05196399 · 36 enrolled · Czechia
  13. Jan 14, 2025Phase 1 study in Drug Drug InteractionIdorsia Pharmaceuticals · NCT06799884 · 19 enrolled · Czechia
  14. May 29, 2026CSPC Pharmaceutical Group's first study: phase 3 study in Resistant HypertensionNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07635914 · 382 planned

Ahead

  1. Dec 28, 2029Primary completion: phase 3 study in Resistant HypertensionCSPC Pharmaceutical Group · NCT07635914

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07635914Resistant Hypertension3Not yet recruitingCSPC Pharmaceutical GroupDec 28, 2029382
NCT06799884Drug Drug Interaction · Czechia1CompletedIdorsia PharmaceuticalsFeb 21, 202519
NCT05196399Healthy Subjects · Czechia1CompletedIdorsia PharmaceuticalsMar 27, 202236
NCT04281342Healthy Subjects · Germany1CompletedIdorsia PharmaceuticalsAug 3, 202148
NCT04252495Liver Diseases · Germany, Poland1CompletedIdorsia PharmaceuticalsApr 5, 202117
NCT04162366Hypertension3WithdrawnIdorsia PharmaceuticalsJun 30, 20210
NCT03586570Healthy Subjects · United States1CompletedIdorsia PharmaceuticalsSep 10, 201820
NCT03541174Resistant Hypertension · United States, Australia, Belgium and more3CompletedIdorsia PharmaceuticalsMay 14, 2021730
NCT03245229Healthy Subjects · Czechia1CompletedIdorsia PharmaceuticalsSep 18, 201720
NCT03165071Renal Insufficiency · Czechia1CompletedIdorsia PharmaceuticalsOct 27, 201716
NCT03100591Healthy Subjects · Netherlands1CompletedIdorsia PharmaceuticalsApr 18, 20176
NCT02841761Healthy Subjects · United States1CompletedIdorsia PharmaceuticalsSep 1, 201620
NCT02708004Healthy Subjects · Switzerland1CompletedIdorsia PharmaceuticalsDec 1, 201624
NCT02603809Essential Hypertension · United States, Canada, Israel and more2CompletedIdorsia PharmaceuticalsFeb 28, 20171,659

How it is read

Names in the registry

  • “Aprocitentan”, 5 entries
  • “Aprocitentan 25 mg”, 4 entries
  • “Aprocitentan tablets(SYH9108)”, 1 entry
  • “Aprocitentan 12.5 mg”, 1 entry
  • “14C-radiolabeled ACT-132577”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.